Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial

Introduction: Angiotensin receptor blockers (ARBs) are preferably used in hypertensive patients with CKD. Azilsartan is a strong antihypertensive ARB, but its antiproteinuric effects are not well understood. We compared the antiproteinuric effect of azilsartan and candesartan in CKD patients in an o...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Takaichi Suehiro, Kazuhiko Tsuruya, Hisako Yoshida, Hiroaki Tsujikawa, Shunsuke Yamada, Shigeru Tanaka, Akihiro Tsuchimoto, Masahiro Eriguchi, Kiichiro Fujisaki, Kumiko Torisu, Toshiaki Nakano, Takanari Kitazono
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Karger Publishers 2021-03-01
Edice:	Kidney & Blood Pressure Research
Témata:	azilsartan candesartan ckd crossover trial proteinuria
On-line přístup:	https://www.karger.com/Article/FullText/512365
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!